Raymond James raised the firm’s price target on ICU Medical to $190 from $158 and keeps an Outperform rating on the shares. The firm sees various sources of potential upside, enhanced by Q2 results, that give it confidence in its estimates, and views ICU Medical as a unique earnings recovery story with the potential to grow EPS at 20%+ over the next two years, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI:
- ICU Medical to Participate in Upcoming Investor Conferences
- ICU Medical price target raised to $158 from $135 at Raymond James
- ICU Medical price target raised to $147 from $136 at KeyBanc
- ICU Medical now sees FY24 adjusted EPS $4.95-$5.35 from $4.40-$5.10
- ICU Medical reports Q2 adjusted EPS $1.56, consensus $1.00
Questions or Comments about the article? Write to editor@tipranks.com